Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake
This article was originally published in The Pink Sheet Daily
Executive Summary
Aggressive clinical trial plan aims to add new indications, build Nexavar oncology franchise on kidney cancer success.
You may also be interested in...
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
Bayer/Onyx’ Nexavar Approved For Kidney Cancer
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.